Sept. 16, 2005 (Athens) — Continuous glucose monitoring may dramatically improve day-to-day management of patients with diabetes, according to data presented here this week at the European Association for the Study of Diabetes 41st annual meeting.

In the GuardControl study, a European multicenter, randomized controlled trial of 162 patients with type 1 diabetes, the group that wore the continuous monitor throughout the trial achieved a substantial decrease in A1C of 1.1 points compared with a 0.4-point reduction for the placebo group. A third group that wore the device intermittently saw a decline in A1C of 0.7 points.